These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37273267)

  • 1. Plasma levels of phosphorylated tau and neurofilament light chain as potential biomarkers for Alzheimer's disease: A biochemical analysis in Pakistani population.
    Faraz Ahmed T; Bilal Azmi M; Imtiaz F; Zaman U; Ahmed A; Shahbaz N
    Saudi Pharm J; 2023 Jul; 31(7):1202-1209. PubMed ID: 37273267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.
    Sun Q; Ni J; Wei M; Long S; Li T; Fan D; Lu T; Shi J; Tian J
    Front Aging Neurosci; 2022; 14():963845. PubMed ID: 36062146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
    Rauchmann BS; Schneider-Axmann T; Perneczky R;
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China.
    Jiao B; Liu H; Guo L; Liao X; Zhou Y; Weng L; Xiao X; Zhou L; Wang X; Jiang Y; Yang Q; Zhu Y; Zhou L; Zhang W; Wang J; Yan X; Tang B; Shen L
    Front Aging Neurosci; 2021; 13():749649. PubMed ID: 34776933
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
    J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.
    Lewczuk P; Ermann N; Andreasson U; Schultheis C; Podhorna J; Spitzer P; Maler JM; Kornhuber J; Blennow K; Zetterberg H
    Alzheimers Res Ther; 2018 Jul; 10(1):71. PubMed ID: 30055655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma tau and neurofilament light chain as biomarkers of Alzheimer's disease and their relation to cognitive functions.
    Abed SS; Hamdan FB; Hussein MM; Al-Mayah QS
    J Med Life; 2023 Feb; 16(2):284-289. PubMed ID: 36937471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase.
    Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM
    Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
    Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
    ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease.
    Kurz C; Stöckl L; Schrurs I; Suridjan I; Gürsel SÜ; Bittner T; Jethwa A; Perneczky R
    J Neurochem; 2023 Apr; 165(1):95-105. PubMed ID: 36625424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
    Huang Y; Li Y; Xie F; Guo Q
    CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds.
    Skoog I; Kern S; Najar J; Guerreiro R; Bras J; Waern M; Zetterberg H; Blennow K; Zettergren A
    J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):983-990. PubMed ID: 33512503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.